SLAS2017 Short Courses

Gene Editing for Drug Discovery

Genome editing tools such as CRISPR-Cas9 are reshaping what is possible within the biological sciences. This course will introduce the possibilities of what can be achieved with genome editing, the current limitations, and the fundamentals of how to apply these technologies to enhance the pursuit of targets and therapeutics.

Who Should Attend:

How You Will Benefit From This Course:

Course Topics:


John G. Doench
Broad Institute of MIT and Harvard

John G. Doench is Associate Director of the Genetic Perturbation Platform at the Broad Institute. He develops and applies the latest approaches in functional genomics, including RNAi, ORF, and CRISPR technologies, to understand the function of genes and how gene dysfunction leads to disease. John collaborates with researchers across many Programs and Initiatives to develop faithful biological models and execute genetic screens. Prior to joining the Broad in 2009, Dr. Doench trained with Phil Sharp at MIT and Ed Harlow at Harvard Medical School. He lives in Jamaica Plain, MA with his wife and daughter.

Samuel A. Hasson
Pfizer, Inc.

Sam Hasson is a Principal Investigator and Lab Head in Pfizer Neuroscience (Cambridge, Massachusetts). His lab focuses on the application of genome editing and high content analysis technologies to validate and develop novel targets in neurodegenerative disease. A major goal of his work is to identify modulators of complex phenotypes in areas such as neuroinflammation and mitochondrial health by utilizing innovative assay design strategies.